Bayer completed the acquisition of KaNDy Therapeutics for $425m.

Bayer, a German multinational pharmaceutical and life sciences company, completed the acquisition of KaNDy Therapeutics, a UK clinical-stage biotech company, from private equity firms Advent Venture Partners, OrbiMed Advisors, Forbion Capital Partners, Longitude Capital Management and Fountain Healthcare Partners, for $425m. “Bayer has been our preferred partner due to its leading position in the area of women’s healthcare. We believe that under the ownership of Bayer, this potential first in class medicine can be optimally developed to become an important non-hormonal treatment option for women suffering vasomotor symptoms due to menopause,” Mary Kerr, KaNDy Therapeutics Co-Founder and CEO.